HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The human renin infused rat: use as an in vivo model for the biological evaluation of human renin inhibitors.

Abstract
The human renin infused rat model (HRIRM) was used as an in vivo small-animal model for evaluating the efficacy of a collection of inhibitors of human renin. The intravenous infusion of recombinant human renin (2.4 microg x kg(-1) x min(-1)) in the ganglion-blocked, nephrectomized rat produced a mean blood pressor response of 47+/-3 mm Hg (1 mm Hg = 133.3 Pa), which was reduced by captopril, enalkiren, and losartan in a dose-dependent manner following oral administration, with ED50 values of 0.3+/-0.1, 2.5+/-0.9, and 5.2+/-1.6 mg/kg, respectively. A series of peptidomimetic P2-P3 butanediamide renin inhibitors inhibited purified recombinant human renin in vitro in a concentration-dependent manner, with IC50 values ranging from 0.4 to 20 nM at pH 6.0, with a higher range of IC50 values (0.8-80 nM) observed at pH 7.4. Following i.v. administration of renin inhibitors, the pressor response to infused human renin in the HRIRM was inhibited in a dose-dependent manner, with ED50 values ranging from 4 to 600 microg/kg. The in vivo inhibition of human renin following i.v. administration in the rat correlated significantly better with the in vitro inhibition of human renin at pH 7.4 (r = 0.8) compared with pH 6.0 (r = 0.5). Oral administration of renin inhibitors also resulted in a dose-dependent inhibition of the pressor response to infused human renin, with ED50 values ranging from 0.4 to 6.0 mg/kg and the identification of six renin inhibitors with an oral potency of <1 mg/kg. The ED50 of renin inhibitors for inhibition of angiotensin I formation in vivo was highly correlated (r = 0.9) with the ED50 for inhibition of the pressor response. These results demonstrate the high potency, dose dependence, and availability following oral administration of the butanediamide series of renin inhibitors.
AuthorsG Bolger, J C Vigeant, F Liard, B Simoneau, D Thibeault, L Pilote, D Lamarre, G Jung, P Anderson, J Jaramillo
JournalCanadian journal of physiology and pharmacology (Can J Physiol Pharmacol) Vol. 77 Issue 11 Pg. 886-95 (Nov 1999) ISSN: 0008-4212 [Print] Canada
PMID10593662 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Dipeptides
  • Ganglionic Blockers
  • Recombinant Proteins
  • enalkiren
  • Angiotensin I
  • Captopril
  • Renin
  • Losartan
Topics
  • Administration, Oral
  • Angiotensin I (biosynthesis)
  • Angiotensin-Converting Enzyme Inhibitors (pharmacology)
  • Animals
  • Antihypertensive Agents (pharmacology)
  • Blood Pressure (drug effects)
  • Captopril (pharmacology)
  • Dipeptides (pharmacology)
  • Dose-Response Relationship, Drug
  • Drug Evaluation, Preclinical
  • Ganglionic Blockers (pharmacology)
  • Humans
  • In Vitro Techniques
  • Losartan (pharmacology)
  • Male
  • Rats
  • Rats, Sprague-Dawley
  • Recombinant Proteins (pharmacology)
  • Renin (antagonists & inhibitors, pharmacology)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: